Graft-versus-host disease impairs vaccine responses through decreased CD4+ and CD8+ T Cell Proliferation and Increased Perforin-Mediated CD8+ T cell apoptosis

Journal of Immunology

Volumn 190, Issue 3, 2013, Pages 1351-1359

  Capitini, Christian M ^a,b,d   Nasholm, Nicole M ^a   Duncan, Brynn B ^b   Guimond, Martin ^c   Fry, Terry J ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADOPTIVE TRANSFER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MALE; MINOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; T LYMPHOCYTE; TREATMENT RESPONSE; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANIMALS, CONGENIC; APOPTOSIS; CANCER VACCINES; CARCINOMA, TRANSITIONAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIVISION; COCULTURE TECHNIQUES; DENDRITIC CELLS; FAS LIGAND PROTEIN; FEMALE; GRAFT VS HOST DISEASE; H-Y ANTIGEN; IMMUNODOMINANT EPITOPES; IMMUNOTHERAPY; LYMPHOCYTE TRANSFUSION; MALE; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; MINOR HISTOCOMPATIBILITY ANTIGENS; PORE FORMING CYTOTOXIC PROTEINS; RADIATION CHIMERA; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTE SUBSETS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; VACCINATION;

EID: 84872695582     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200391     Document Type: Article

References (44)

1. Crooks, G. M., K. Weinberg, and C. Mackall. 2006. Immune reconstitution: From stem cells to lymphocytes. Biol. Blood Marrow Transplant. 12(1 Suppl. 1): 42-46. (Pubitemid 43034118)
2. Dulude, G., D.-C. Roy, and C. Perreault. 1999. The effect of graft-versus-host disease on T cell production and homeostasis. J. Exp. Med. 189: 1329-1342.
3. Hebib, N. C., O. Déas, M. Rouleau, A. Durrbach, B. Charpentier, F. Beaujean, J. P. Vernant, and A. Senik. 1999. Peripheral blood T cells generated after allogeneic bone marrow transplantation: Lower levels of bcl-2 protein and enhanced sensitivity to spontaneous and CD95-mediated apoptosis in vitro. Abrogation of the apoptotic phenotype coincides with the recovery of normal naive/primed T-cell profiles. Blood 94: 1803-1813. (Pubitemid 29411332)
4. Lin, M.-T., L.-H. Tseng, H. Frangoul, T. Gooley, J. Pei, A. Barsoukov, Y. Akatsuka, and J. A. Hansen. 2000. Increased apoptosis of peripheral blood T cells following allogeneic hematopoietic cell transplantation. Blood 95: 3832-3839. (Pubitemid 30412857)
5. Brochu, S., B. Rioux-Massé, J. Roy, D.-C. Roy, and C. Perreault. 1999. Massive activation-induced cell death of alloreactive T cells with apoptosis of bystander postthymic T cells prevents immune reconstitution in mice with graft-versushost disease. Blood 94: 390-400. (Pubitemid 29323852)
6. Brugnoni, D., P. Airo, M. Pennacchio, G. Carella, A. Malagoli, A. G. Ugazio, F. Porta, and R. Cattaneo. 1999. Immune reconstitution after bone marrow transplantation for combined immunodeficiencies: Down-modulation of Bcl-2 and high expression of CD95/Fas account for increased susceptibility to spontaneous and activation-induced lymphocyte cell death. Bone Marrow Transplant. 23: 451-457. (Pubitemid 29117035)
7. Gorski, J., X. Chen, M. Gendelman, M. Yassai, A. Krueger, E. Tivol, B. Logan, R. Komorowski, S. Vodanovic-Jankovic, and W. R. Drobyski. 2007. Homeostatic expansion and repertoire regeneration of donor T cells during graft versus host disease is constrained by the host environment. Blood 109: 5502-5510. (Pubitemid 46890576)
8. Alpdogan, S. O., S. X. Lu, N. Patel, S. McGoldrick, D. Suh, T. Budak-Alpdogan, O. M. Smith, J. Grubin, C. King, G. L. Goldberg, et al. 2008. Rapidly proliferating CD44hi peripheral T cells undergo apoptosis and delay posttransplantation T-cell reconstitution after allogeneic bone marrow transplantation. Blood 112: 4755-4764.
9. Beatty, G. L., J. S. Smith, R. Reshef, K. P. Patel, T. A. Colligon, B. A. Vance, N. V. Frey, F. B. Johnson, D. L. Porter, and R. H. Vonderheide. 2009. Functional unresponsiveness and replicative senescence of myeloid leukemia antigenspecific CD8+ T cells after allogeneic stem cell transplantation. Clin. Cancer Res. 15: 4944-4953.
10. Donnenberg, A. D., J. B. Margolick, L. A. Beltz, V. S. Donnenberg, and C. R. Rinaldo, Jr. 1995. Apoptosis parallels lymphopoiesis in bone marrow transplantation and HIV disease. Res. Immunol. 146: 11-21.
11. Perales, M.-A., A. Diab, A. D. Cohen, D. W. Huggins, J. A. Guevara-Patino, V. M. Hubbard, M. E. Engelhorn, A. A. Kochman, J. M. Eng, F. Mortazavi, et al. 2006. DNA immunization against tissue-restricted antigens enhances tumor immunity after allogeneic hemopoietic stem cell transplantation. J. Immunol. 177: 4159-4167. (Pubitemid 44359951)
12. Capitini, C. M., S. Herby, M. Milliron, M. R. Anver, C. L. Mackall, and T. J. Fry. 2009. Bone marrow deficient in IFN-gamma signaling selectively reverses GVHD-associated immunosuppression and enhances a tumor-specific GVT effect. Blood 113: 5002-5009.
13. Anderson, L. D., Jr., C. A. Savary, and C. A. Mullen. 2000. Immunization of allogeneic bone marrow transplant recipients with tumor cell vaccines enhances graft-versus-tumor activity without exacerbating graft-versus-host disease. Blood 95: 2426-2433. (Pubitemid 30167746)
14. Teshima, T., N. Mach, G. R. Hill, L. Pan, S. Gillessen, G. Dranoff, and J. L. Ferrara. 2001. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T-cell-depleted bone marrow transplantation. Cancer Res. 61: 162-171. (Pubitemid 32095714)
15. Anderson, L. D., Jr., S. Mori, S. Mann, C. A. Savary, and C. A. Mullen. 2000. Pretransplant tumor antigen-specific immunization of allogeneic bone marrow transplant donors enhances graft-versus-tumor activity without exacerbation of graft-versus-host disease. Cancer Res. 60: 5797-5802.
16. Moyer, J. S., G. Maine, and J. J. Mulé. 2006. Early vaccination with tumorlysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects. Biol. Blood Marrow Transplant. 12: 1010-1019.
17. Falkenburg, J. H. F., H. E. Heslop, and A. J. Barrett. 2008. T cell therapy in allogeneic stem cell transplantation. Biol. Blood Marrow Transplant. 14(1 Suppl. 1): 136-141. (Pubitemid 350286852)
18. Manzo, T., R. Hess Michelini, V. Basso, A. Ricupito, J.-G. Chai, E. Simpson, M. Bellone, and A. Mondino. 2011. Concurrent allorecognition has a limited impact on posttransplant vaccination. J. Immunol. 186: 1361-1368.
19. Jenq, R. R., C. G. King, C. Volk, D. Suh, O. M. Smith, U. K. Rao, N. L. Yim, A. M. Holland, S. X. Lu, J. L. Zakrzewski, et al. 2009. Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. Blood 113: 1574-1580.
20. Valujskikh, A., O. Lantz, S. Celli, P. Matzinger, and P. S. Heeger. 2002. Crossprimed CD8(+) T cells mediate graft rejection via a distinct effector pathway. Nat. Immunol. 3: 844-851.
21. Lantz, O., I. Grandjean, P. Matzinger, and J. P. Di Santo. 2000. Gamma chain required for naive CD4+ T cell survival but not for antigen proliferation. Nat. Immunol. 1: 54-58.
22. Capitini, C. M., J. P. E. Davis, S. M. Larabee, S. Herby, N. M. Nasholm, and T. J. Fry. 2011. Extracorporeal photopheresis attenuates murine graft-versus-host disease via bone marrow derived interleukin-10 and preserves responses to dendritic cell vaccination. Biol. Blood Marrow Transplant. 17: 790-799.
23. Guimond, M., R. G. Veenstra, D. J. Grindler, H. Zhang, Y. Cui, R. D. Murphy, S. Y. Kim, R. Na, L. Hennighausen, S. Kurtulus, et al. 2009. Interleukin 7 signaling in dendritic cells regulates the homeostatic proliferation and niche size of CD4+ T cells. Nat. Immunol. 10: 149-157.
24. Melchionda, F., T. J. Fry, M. J. Milliron, M. A. McKirdy, Y. Tagaya, and C. L. Mackall. 2005. Adjuvant IL-7 or IL-15 overcomes immunodominance and improves survival of the CD8+ memory cell pool. J. Clin. Invest. 115: 1177-1187. (Pubitemid 40629036)
25. Perez-Diez, A., N. T. Joncker, K. Choi, W. F. N. Chan, C. C. Anderson, O. Lantz, and P. Matzinger. 2007. CD4 cells can be more efficient at tumor rejection than CD8 cells. Blood 109: 5346-5354. (Pubitemid 46890556)
26. Suchin, E. J., P. B. Langmuir, E. Palmer, M. H. Sayegh, A. D. Wells, and L. A. Turka. 2001. Quantifying the frequency of alloreactive T cells in vivo: New answers to an old question. J. Immunol. 166: 973-981. (Pubitemid 32060253)
27. Lee, S. J., S. Y. Chong, J. W. Lee, S. C. Kim, Y. H. Min, J. S. Hahn, and Y. W. Ko. 1997. Difference in the expression of Fas/Fas-ligand and the lymphocyte subset reconstitution according to the occurrence of acute GVHD. Bone Marrow Transplant. 20: 883-888. (Pubitemid 27493928)
28. Via, C. S., P. Nguyen, A. Shustov, J. Drappa, and K. B. Elkon. 1996. A major role for the Fas pathway in acute graft-versus-host disease. J. Immunol. 157: 5387-5393. (Pubitemid 126448957)
29. Shustov, A., P. Nguyen, F. Finkelman, K. B. Elkon, and C. S. Via. 1998. Differential expression of Fas and Fas ligand in acute and chronic graft-versus-host disease: Up-regulation of Fas and Fas ligand requires CD8+ T cell activation and IFN-gamma production. J. Immunol. 161: 2848-2855. (Pubitemid 28425706)
30. Wasem, C., C. Frutschi, D. Arnold, C. Vallan, T. Lin, D. R. Green, C. Mueller, and T. Brunner. 2001. Accumulation and activation-induced release of preformed Fas (CD95) ligand during the pathogenesis of experimental graft-versus-host disease. J. Immunol. 167: 2936-2941. (Pubitemid 32768929)
31. Schmaltz, C., O. Alpdogan, K. J. Horndasch, S. J. Muriglan, B. J. Kappel, T. Teshima, J. L. Ferrara, S. J. Burakoff, and M. R. van den Brink. 2001. Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect. Blood 97: 2886-2895.
32. Baker, M. B., R. L. Riley, E. R. Podack, and R. B. Levy. 1997. Graft-versus-hostdisease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc. Natl. Acad. Sci. USA 94: 1366-1371.
33. Baker, M. B., N. H. Altman, E. R. Podack, and R. B. Levy. 1996. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J. Exp. Med. 183: 2645-2656. (Pubitemid 26192373)
34. Braun, M. Y., B. Lowin, L. French, H. Acha-Orbea, and J. Tschopp. 1996. Cytotoxic T cells deficient in both functional fas ligand and perforin show residual cytolytic activity yet lose their capacity to induce lethal acute graft-versushost disease. J. Exp. Med. 183: 657-661. (Pubitemid 26059524)
35. Maeda, Y., R. B. Levy, P. Reddy, C. Liu, S. G. Clouthier, T. Teshima, and J. L. Ferrara. 2005. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 105: 2023-2027. (Pubitemid 40731787)
36. Hattori, K., T. Hirano, H. Miyajima, N. Yamakawa, M. Tateno, K. Oshimi, N. Kayagaki, H. Yagita, and K. Okumura. 1998. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 91: 4051-4055. (Pubitemid 28261965)
37. Tsukada, N., T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura. 1999. Graftversus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation. Blood 93: 2738-2747. (Pubitemid 29181207)
38. Graubert, T. A., J. F. DiPersio, J. H. Russell, and T. J. Ley. 1997. Perforin/ granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation. J. Clin. Invest. 100: 904-911. (Pubitemid 27371709)
39. Blazar, B. R., P. A. Taylor, and D. A. Vallera. 1997. CD4+ and CD8+ T cells each can utilize a perforin-dependent pathway to mediate lethal graft-versus-host disease in major histocompatibility complex-disparate recipients. Transplantation 64: 571-576. (Pubitemid 27377186)
40. Alpdogan, O., J. M. Eng, S. J. Muriglan, L. M. Willis, V. M. Hubbard, K. H. Tjoe, T. H. Terwey, A. Kochman, and M. R. van den Brink. 2005. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood 105: 865-873. (Pubitemid 40070777)
41. Alpdogan, O., S. J. Muriglan, J. M. Eng, L. M. Willis, A. S. Greenberg, B. J. Kappel, and M. R. van den Brink. 2003. IL-7 enhances peripheral T cell reconstitution after allogeneic hematopoietic stem cell transplantation. J. Clin. Invest. 112: 1095-1107. (Pubitemid 38056324)
42. Capitini, C. M., T. J. Fry, and C. L. Mackall. 2009. Cytokines as adjuvants for vaccine and cellular therapies for cancer. Am. J. Immunol. 5: 65-83.
43. Sinha, M. L., T. J. Fry, D. H. Fowler, G. Miller, and C. L. Mackall. 2002. Interleukin 7 worsens graft-versus-host disease. Blood 100: 2642-2649.
44. Grossman, W. J., J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson, and T. J. Ley. 2004. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589-601. (Pubitemid 39370513)